Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The efficacy of ixazomib for the treatment of R/R myeloma

In this video, Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, briefly discusses the efficacy of ixazomib, an oral proteasome inhibitor, for the treatment of relapsed/refractory (R/R) myeloma. Prof. Jackson also comments on the importance of this efficacious agent during the COVID-19 pandemic. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Transcript (edited for clarity)

Ixazomib is an orally active proteasome inhibitor and there is little doubt that the TOURMALINE data show that it, in combination with Revlimid and dexmethasone in relapsed/refractory multiple myeloma is efficacious. And in terms of treatment delivery, we’ve seen that there really has been a large move towards using ixazomib during the COVID pandemic because it’s meant patients haven’t got to come into hospital, it’s meant they haven’t had to wait for an outpatient slot for their treatment, and yet we’ve still got an effective therapy...

Ixazomib is an orally active proteasome inhibitor and there is little doubt that the TOURMALINE data show that it, in combination with Revlimid and dexmethasone in relapsed/refractory multiple myeloma is efficacious. And in terms of treatment delivery, we’ve seen that there really has been a large move towards using ixazomib during the COVID pandemic because it’s meant patients haven’t got to come into hospital, it’s meant they haven’t had to wait for an outpatient slot for their treatment, and yet we’ve still got an effective therapy. And again, one of the things I think the pandemic has taught us is that patient time is an important gift we can give back to them. And so, the advantages of an oral a

Read more...

Disclosures

Speaker honoraria engagements: Amgen, Takeda, Johnson & Johnson, Sanofi, Celgene and Roche; Research funding: Takeda, Onyx and Celgene; Advisory Boards: Amgen, Takeda, Johnson & Johnson, Oncopeptides, Pfizer, Sanofi, Celgene, GSK and Roche; Board of directors Myeloma UK.